The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
Open accessAbstract
BACKGROUND: The incremental economic burden of US adults with major depressive disorder (MDD) was estimated at $US210.5 billion in 2010 (year 2012 values). OBJECTIVE: Following a similar methodology, this study updates the previous findings with more recent data to report the economic burden of adults with MDD in 2018. METHOD: This study used a framework for evaluating the incremental economic burden of adults with MDD in the USA that combined original and literature-based estimates, focusing on key changes between 2010 and 2018. The prevalence rates of MDD by sex, age, employment, and treatment status over time were estimated based on the National Survey on Drug Use and Health (NSDUH). The incremental direct and workplace costs per individual with MDD were primarily derived from administrative claims data and NSDUH data using comparative analyses of individuals with and without MDD. Societal direct and workplace costs were extrapolated by multiplying NSDUH estimates of the number of people with MDD by the direct and workplace cost estimates per patient. The suicide-related costs were estimated using a human capital method. RESULTS: The number of US adults with MDD increased by 12.9%, from 15.5 to 17.5 million, between 2010 and 2018, whereas the proportion of adults with MDD aged 18-34 years increased from 34.6 to 47.5%. Over this period, the incremental economic burden of adults with MDD increased by 37.9% from $US236.6 billion to 326.2 billion (year 2020 values). All components of the incremental economic burden increased (i.e., direct costs, suicide-related costs, and workplace costs), with the largest growth observed in workplace costs, at 73.2%. Consequently, the composition of 2018 costs changed meaningfully, with 35% attributable to direct costs (47% in 2010), 4% to suicide-related costs (5% in 2010), and 61% to workplace costs (48% in 2010). This increase in the workplace cost share was consistent with more favorable employment conditions for those with MDD. Finally, the proportion of total costs attributable to MDD itself as opposed to comorbid conditions remained stable at 37% (38% in 2010). CONCLUSION: Workplace costs accounted for the largest portion of the growing economic burden of MDD as this population trended younger and was increasingly likely to be employed. Although the total number of adults with MDD increased from 2010 to 2018, the incremental direct cost per individual declined. At the same time, the proportion of adults with MDD who received treatment remained stable over the past decade, suggesting that substantial unmet treatment needs remain in this population. Further research is warranted into the availability, composition, and quality of MDD treatment services.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The current estimate of total incremental costs of MDD in 2019 represents a 3.5% increase in the burden compared with a prior estimate in 2018 (when standardized to 2019 values), with 36.0% of the total incremental costs of MDD in 2019 coming from novel components not previously included in the prior estimate (i.e., unemployment, all-cause mortality, householdrelated costs) [8].”
From The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) (2023) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“one of the key differentiators of the current study from previous estimations of the economic burden of MDD [8,33,34] was the consideration of household-related costs.”
From The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) (2023) · cites this paper as [8]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The COVID-19 pandemic exacerbated many risk factors for depression across countries of disparate economic status 5,6 ;”
From Digital health technologies and major depressive disorder (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“The current estimate of total incremental costs of MDD in 2019 represents a 3.5% increase in the burden compared with a prior estimate in 2018 (when standardized to 2019 values), with 36.0% of the total incremental costs of MDD in 2019 coming from novel components not previously included in the prior estimate (i.e., unemployment, all-cause mortality, householdrelated costs) [8].”
From The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) (2023) · cites this paper as [8]
In the citing paper
“which was an increase from the previous estimate of 7.1% in 2018 [8].”
From The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) (2023) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Centers for Disease Control and Prevention
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n74 · Cited by 6,444
Quan, H., Li, B., Couris, C. M., Fushimi, K., Graham, P., Hider, P., Januel, J.-M., & Sundararajan, V. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq433 · Cited by 5,843
The outbreak of COVID-19 coronavirus and its impact on global mental health
Torales, J., O’Higgins, M., Castaldelli-Maia, J. M., & Ventriglio, A. (2020) · International Journal of Social Psychiatry · doi:10.1177/0020764020915212 · Cited by 3,013
Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic
Ettman, C. K., Abdalla, S. M., Cohen, G. H., Sampson, L., Vivier, P. M., & Galea, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19686 · Cited by 2,138
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Self-citationMokdad (2018) · doi:10.1001/jama.2018.0158 · Cited by 1,517
Depression Is the Leading Cause of Disability Around the World
Friedrich, M. J. (2017) · JAMA · doi:10.1001/jama.2017.3826 · Cited by 1,459
Liu, Q., He, H., Yang, J., Feng, X., Zhao, F., & Lyu, J. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.002 · Cited by 1,452
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“46,47 Furthermore, compared to people without depression, patients with MDD have been demonstrated to have a shorter life expectancy.”
BackgroundMajor Depression and Its Recurrences: Life Course Matters
Monroe, S. M., & Harkness, K. L. (2022) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072220-021440 · Cited by 608
The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)
Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S.-Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A.-A., & Kessler, R. C. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02622-x · Cited by 223
Self-citationMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Blood brain barrier and inflammation in depression
Medina-Rodriguez, E. M., & Beurel, E. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105926 · Cited by 123
Metadata
- Authors
- Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Simes, M., Berman, R., Koenigsberg, S. H., & Kessler, R. C.
- Affiliations
- Analysis Group (United States) (US)
- Harvard University (US)
- Venue
- PharmacoEconomics
- Published
- 2021-05-05
- Volume
- 39
- Issue
- 6
- Pages
- 653-665
- ISSN
- 1170-7690 (ISSN-L)
- 1179-2027
- PMC
- PMC8097130
- OpenAlex
- W3157759986
- Cited by
- 838
- References
- 32
- Citations by year
- 2026: 123 · 2025: 204 · 2024: 221 · 2023: 177 · 2022: 95 · 2021: 14
- FWCI
- 124.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- PharmacoEconomics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- major depressive disorder, economic burden, direct medical costs, human capital, depression prevalence, comorbidities, United States adults, National Survey on Drug Use and Health, administrative claims data, productivity loss, age and sex differences
- MeSH terms
- Adult, Major Depressive Disorder, Humans, United States, Prevalence, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). https://app.cochat.ai/papers/10.1007/s40273-021-01019-4
- The paper
- Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Simes, M., Berman, R., Koenigsberg, S. H., & Kessler, R. C. (2021). The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). PharmacoEconomics. https://doi.org/10.1007/s40273-021-01019-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.